Slide 1: Q1 2023 Business Update
Q1 2023 Business Update 10 MAY 2023
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. 2
Slide 3: Speakers on Today's Call
Speakers on Today’s Call Mondher Mahjoubi Joyson Karakunnel Yannis Morel Frédéric Lombard MD MD, MSc, FACP PhD MBA (Q&A) Chief Executive Officer Chief Medical Officer Head of Business Development Chief Financial Officer and Product Portfolio Strategy Chairman of the Executive Board
Slide 4: Scientific innovation drives our strategy
Scientific innovation drives our strategy Our ambition – leverage our scientific know-how in innate Advance our Build a sustainable Drive near-term value immunity and antibody engineering to innovative business through with lacutamab develop cancer drugs that improve the Drive near-term value pipeli
Slide 5: Our robust pipeline of proprietary & partnered assets
Our robust pipeline of proprietary & partnered assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Upcoming Milestone Sezary syndrome TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) Final data H2 2023 Mycosis Fungoides TELLOMAK Final data H2 2023 Lacutamab KIR3DL2 PTCL (combo with
Slide 6: Lacutamab | Development strategy
LACUTAMAB Lacutamab | Development strategy A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 treatment. Cutaneous T cell lymphoma TELLOMAK Sézary syndrome Sezary Phase 2 Trial Sézary syndrome 80-200 patients Phase 2 >90% KIR3DL2 expression Cohort 1 (N~60) 3 cohorts (N~100)
Slide 7: Lacutamab | Preliminary efficacy results in CTCL support further development
LACUTAMAB Lacutamab | Preliminary efficacy results in CTCL support further development Final data from TELLOMAK Phase 2 trial in H2 2023 Sézary syndrome Best global response Best skin response Best blood response 21.6% 35.1% 37.8% Cohort 1 (N~60) Minimum of 2 prior therapies, including mogamulizumab
Slide 8: Monalizumab development in progress of Phases 2 and 3 trials
MONALIZUMAB Monalizumab development in progress of Phases 2 and 3 trials Covering early stages of lung cancer Stages of the disease Upcoming presentation NeoCOAST* Data presented: 2022 NeoCOAST-2* 30% major pathological Patients with Stage II to IIIB NSCLC NSCLC response vs. 11% durvalumab. Monalizu
Slide 9: Proprietary NK cell engager platform
ANKET® Proprietary NK cell engager platform Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46. Provides proliferation and activation signals targeted to NK cells. Demonstrates better anti-tumor efficacy than approved benchmar
Slide 10: ANKET NK cell engager molecules have the potential to strongly control tumor proliferation
ANKET® ANKET® NK cell engager molecules have the potential to strongly control tumor proliferation via the proliferation and activation of NK cells Growing clinical pipeline Innate Pharma differentiated MoA IPH6101 / SAR’579 (CD123) Phase 1 Nature Biotechnology January 2023 IPH6401 / SAR’514 (BCMA)
Slide 11: IPH6101/SAR'579 Oral presentation at ASCO 2023
ANKET® IPH6101/SAR’579 Oral presentation at ASCO 2023 IPH6101/SAR’579 is the first NKp46/CD16-based NK cell engager using Innate’s proprietary multispecific antibody format ANKET® Preclinical rationale Abstract selected for an oral presentation at the 2023 ASCO Annual Congress IPH6101 induced AML ca
Slide 12: Strategic partnership between Sanofi and Innate
ANKET® Strategic partnership between Sanofi and Innate Three molecules licensed to Sanofi plus two undisclosed targets under options IPH6101/SAR’579 IPH6401/SAR’514 IPH62 OPTION Ongoing CD123 BCMA B7-H3 2 undisclosed programs Phase 1 in AML Progression towards IND Research targets Payments received
Slide 13: Partnership between Takeda and Innate
Partnership between Takeda and Innate Exclusive worldwide rights to develop, manufacture and commercialize Antibody Drug Conjugates (ADC) ADC using a panel of selected antibodies developed by Innate Ongoing Undisclosed target programs Preclinical stage – with a primary focus in Celiac disease Paymen
Slide 14: Upcoming catalysts
Upcoming catalysts Delivering across our strategic objectives • Monalizumab PACIFIC-9 | Phase 3 readout (AZ) • Monalizumab NeoCOAST-2 | Phase 2 readout (AZ) • IPH5201(CD39) MATISSE | Phase 2 readout (AZ) • IPH6101 / SAR’579 ANKET ® (CD123) | Phase 1 • IPH6101 / SAR’579 ANKET® (CD123) | Next steps (S
Slide 15: Abstracts to be presented by Innate's partners at the 2023 ASCO Annual Meeting
Abstracts to be presented by Innate’s partners at the 2023 ASCO Annual Meeting June 2-6 2023 IPH6101 / SAR’5791 PACIFIC-9 NEOCOAST-2 Oral presentation1 Trial in progress Poster2 Trial in progress Poster3 Phase 1 PHASE 1 PHASE 3 PHASE 2 Participants of at least 12 years of age with Patients with Stag
Slide 16: Key Takeaways
Key Takeaways Create value for patients and shareholders Strategic Priorities Robust pipeline of Antibody engineering capabilities Advancing lacutamab Maximizing ANKET® platform Continuing to explore ADC Early R&D focus to drive value through later stage Track record of strategic partnerships AstraZ
Slide 17: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA